Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cardiac fibroblast differentiation is a developmental and pathological process in which precursor cells, typically of epicardial, endocardial, or neural crest origin, become cardiac fibroblasts. This occurs largely through epithelial-to-mesenchymal transition (EMT) regulated by various signaling pathways, such as TGFβ, FGF, PDGFRα, and Wnt. These fibroblasts contribute structurally and functionally to the heart during development, participate in extracellular matrix production, and are key mediators of cardiac fibrosis and remodeling following injury.
Modulation of signaling pathways impacting fibroblast differentiation (e.g., TGFβ inhibition, Wnt or FGF pathway modulation)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cardiac fibroblast differentiation.